

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number
WO 2005/074989 A2

(51) International Patent Classification⁷: **A61K 45/06**,
A61P 35/00, A61K 31/401, 31/4745

(21) International Application Number:
PCT/EP2005/001180

(22) International Filing Date: 4 February 2005 (04.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/541,984 5 February 2004 (05.02.2004) US

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **ZAWEL, Leigh** [US/US]; 13 Patriots Way, Hingham, MA 02043 (US).

(74) Agent: **ROTH, Peter, R.**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR

(57) Abstract: The invention relates to a pharmaceutical combination which comprises (a) a DNA topoisomerase inhibitor compound and (b) a compound that inhibits the caspase-9 inhibiting properties of an inhibitor of apoptosis protein (IAP) for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.



WO 2005/074989 A2